High-Throughput Isolation of Nanomouse-Derived VHH Domains: A Practical Guide from Immunization to Nanobody Expression.

Authors

Tessa J Casselman, Asa W Huffaker, Kristie C Mitchell, Jamie E Schnarrs, Sylvia Ni, Mary E Skinner, Matthias C Truttmann

Published in

Current protocols. Volume 6. Issue 7. Pages e70432.

Abstract

Nanobodies are small but specific heavy chain-only antibody fragments. Their small size, relative stability, and ability to access difficult to reach deep-tissue antigens makes them valuable research, diagnostic, and therapeutic tools. Nanobodies are derived from the variable heavy (VH) domain of heavy chain-only antibodies that are unique to camelids, including alpacas, llamas, and camels. The approaches employed to produce nanobodies, have been evolving and expanding since the initial discovery of heavy chain-only antibodies 30 years ago. Traditional nanobody development involves camelid immunization with a soluble, purified protein, followed by blood collection and processing, enrichment for potent nanobody sequences, and eventual expression and purification of candidate nanobodies for testing and validation. Alternative nanobody generation strategies aim to identify novel nanobodies utilizing synthetic or animal-derived naïve nanobody libraries in combination with phage-, yeast surface-, or ribosome displays for nanobody selection. This article outlines a novel protocol series for nanobody production using a commercially available transgenic "nanomouse", engineered to produce heavy chain-only antibodies containing camelid VH domains from alpacas, dromedaries, and Bactrian camels. These protocols will cover the following aspects: (1) Nanomouse breeding, genotyping, and colony establishment; (2) Nanomouse immunization and tissue collection; (3) RNA extraction from nanomouse immune cells isolated from blood and tissues; (4) Generation and amplification of VHH DNA from nanomouse cDNA; (5) Digestion of VHH DNA and ligation into a phagemid expression vector; (6) Preparation of a screenable Escherichia coli TG1-based phagemid library; (7) Antigen-driven VHH selection using phage display; (8) Single colony VHH ELISA screening; (9) Sequencing of ELISA hits and candidate VHH sequence identification; (10) Geneblock design of candidate VHH and Gibson Assembly into a nanobody expression vector; and (11) Nanobody over-expression and purification. We provide a comprehensive toolkit to facilitate nanobody development and make it more accessible to the greater research community. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Nanomouse breeding, genotyping, and colony establishment Basic Protocol 2: Nanomouse immunization and tissue collection Basic Protocol 3: RNA extraction from nanomouse immune cells isolated from blood and tissues Basic Protocol 4: Generation and amplification of VHH DNA from nanomouse cDNA Basic Protocol 5: Digestion of VHH DNA and ligation into a phagemid expression vector Basic Protocol 6: Preparation of a screenable E. coli TG1-based phagemid library Basic Protocol 7: Antigen-driven VHH selection using phage display Basic Protocol 8: Single colony VHH enzyme-linked immunosorbent assay (ELISA) screening Basic Protocol 9: Sequencing of ELISA hits and candidate VHH sequence identification Basic Protocol 10: Geneblock design of candidate VHH and Gibson Assembly into a nanobody expression vector Basic Protocol 11: Nanobody over-expression and purification.

PMID:
42479849
Bibliographic data and abstract were imported from PubMed on 22 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.